No Data
No Data
China Accepts Jiangsu Aidea Pharma's New Indication for HIV Medication
Investor Optimism Abounds Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) But Growth Is Lacking
Jiangsu Aidea Pharmaceutical Withdraws Marketing Authorization Application for HIV Tablets
Jiangsu Aidea Pharmaceutical (688488.SH): Withdrawal of the new indication application for Aino Weilin tablets.
Gelonghui September 26th | jiangsu aidea pharmaceutical (688488.SH) announced that the company has scientifically formulated differentiated market strategy based on evidence-based medicine data, product characteristics, patent duration, etc. for antiretroviral drugs. According to the company's market strategy, the company has proactively applied to withdraw the marketing authorization application for the new indication of enofovir tablets, and has recently obtained approval from the National Medical Products Administration. As of the date of this announcement, the single-compound formulation of enofoside tablets containing enofoside as an ingredient has made smooth progress in the application for new indications, and its marketing authorization application has completed the technical review work, and is currently in the process of document preparation and review and approval. The company will continue
Star Evening News | Xi'an Bright Laser Technologies plans to invest 1 billion yuan to build a material production line. Jiangsu Aidea Pharmaceutical has completed the acquisition of 31.161% equity of Nanda Pharmaceuticals.
1. Guangdong Jiayuan Technology signed the "Investment Intention Termination Agreement" with the Meixian District People's Government of Meizhou City; 2. Xi'an Bright Laser Technologies, opt machine vision tech co., ltd., NAIKE Equipment disclosed the repurchase plan; 3. Shanghai Allist Pharmaceuticals Co., Ltd.: AST2303 slice obtained the drug clinical trial approval notice.
Aidea Pharma Pledges Subsidiary's 51% Stake for 90 Million Yuan Loan; Shares Drop 5%
No Data
No Data